ArticleClinicoEconomics and outcomes research : CEOR2019

Cost-effectiveness of fractional exhaled nitric oxide (FeNO) measurement in predicting response to omalizumab in asthma.

Elizabeth A Brooks et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.